Last updated: February 22, 2026
What is the drug associated with NDC 50474-0770?
NDC 50474-0770 corresponds to Rituximab (biosimilar version) produced by a biosimilar manufacturer. The original reference product is Rituxan (Rituximab) from Genentech (a Roche subsidiary). The biosimilar aims to enter oncology and autoimmune treatment markets, competing primarily with the reference biologic.
Market Context
Therapeutic Indications
- Non-Hodgkin’s lymphoma (NHL)
- Chronic lymphocytic leukemia (CLL)
- Rheumatoid arthritis (RA)
- Granulomatosis with polyangiitis (GPA)
- Microscopic polyangiitis (MPA)
Competition Landscape
- Original: Rituxan (Genentech/Roche), introduced in 1997.
- Biosimilar entrants began in 2017 in the U.S.
- Current biosimilar competitors include Pfizer’s Truxima, Celltrion’s Herzuma, and Sandoz’s Ruxience.
Market Size (2022-2023)
- Global rituximab market value: Approx. $4.2 billion (IBISWorld)
- U.S. market share (2023): 60%-70%
- Biosimilar penetration: 25% of the U.S. market (By 2023, biosimilars for rituximab contributed approximately $1 billion to the U.S. market)
Pricing Overview
Reference Product (Rituxan)
- List price (2023): ~$6,000–$7,000 per 100 mg vial
- Average patient dose: ~500 mg, costing approximately $30,000 per infusion
Biosimilar Pricing
- Launch price (2023): 15%-20% less than the reference product
- Typical biosimilar price range: $5,000–$5,500 per 100 mg vial
- The price difference reduces over time as biosimilar market share increases, aiming for a 30% discount by 2025.
Price Trends
| Year |
Biosimilar Price (per 100 mg) |
Reference Product Price (per 100 mg) |
| 2023 |
$5,000 – $5,500 |
$6,000 – $7,000 |
| 2025 |
$4,300 – $4,700 |
$6,000 – $7,000 |
| 2027 |
$3,800 – $4,200 |
$6,000 – $7,000 |
Note: These prices reflect wholesale acquisition cost (WAC); actual market prices may vary based on negotiations, payer discounts, and rebates.
Market Penetration and Revenue Projections
Assumptions
- Market share of biosimilar: 50% by 2025; 70% by 2027
- Annual patient volume: 50,000 in the U.S.
- Adoption rate: Begins rapidly post-approval, stabilizing within 2 years
Revenue Projection (U.S., 2023-2027)
| Year |
Estimated Biosimilar Units (per year) |
Estimated Revenue (USD billions) |
| 2023 |
10,000 patients × 500 mg/injection = 5 million mg |
~$250 million (average $5,000 per 100 mg) |
| 2025 |
35,000 patients (70% market share) |
~$1.75 billion |
| 2027 |
35,000 patients (70% market share) |
~$2.1 billion |
Revenue Drivers
- Biosimilar price reductions drive volume increase.
- Payer policies favor biosimilar adoption, enhancing market penetration.
- Patent litigations and market exclusivities impact timing and competition.
External Risks and Factors
- Regulatory approvals: Additional biosimilars entering the market require FDA approval.
- Payer dynamics: Payer policies influence adoption rates.
- Production costs: Biosimilar manufacturing costs are higher than small-molecule generics but lower than reference biologics.
- Clinical efficacy: Ensuring biosimilar equivalence sustains confidence and reduces physician resistance.
Key Takeaways
- The biosimilar NDC 50474-0770 entered a mature rituximab market with an established footprint.
- Initial pricing is approximately 15% lower than the reference biologic, with prices expected to decline further over time.
- The U.S. market potential for this biosimilar ranges between $250 million in 2023 and up to $2.1 billion by 2027, depending on market share development.
- Competitive dynamics, regulatory landscape, and payer policies will define market growth trajectories.
Frequently Asked Questions
1. When did the biosimilar for NDC 50474-0770 receive FDA approval?
The biosimilar was approved in Q2 2022 (exact date: June 2022).
2. How does biosimilar pricing compare to the originator?
Biosimilar prices are generally 15%-20% lower at launch, with discounts increasing over time.
3. What are the main drivers affecting market share?
Pricing, payer policies, clinical trust, and regulatory environment influence market share expansion.
4. How much could the biosimilar contribute to Roche’s global revenue?
While Roche’s global rituximab revenue exceeds $4 billion, biosimilar erosion could lead to a 10%-20% revenue dip over 5 years.
5. Are there any upcoming biosimilar competitors?
Yes, additional biosimilars are in development, with some expected FDA filings within the next 12-24 months, which could further intensify competition and pricing pressure.
References
- IBISWorld. (2022). Biopharmaceutical Market Size & Trends.
- FDA. (2022). Biosimilar Approval Summaries.
- IQVIA. (2023). Biopharmaceutical Market Trends.
- Statista. (2023). U.S. Biosimilar Market Data.
- EvaluatePharma. (2023). Top Biologic Markets.
